Thread by @tycoonmindset05

Laurus Laboratories concall was today at 10:00 AM

"The big becoming bigger "

Here are the concall details

@unseenvalue @nid_rockz @punitbansal14 @saketreddy

Business Updates:
• Oncology business is expected to grow well.
• CRM manufacturing of API and ARV and Non ARV segment is seen good growth.
• Adding manufacturing facility for ARV and Non ARV.
• Revenue share mentioned in image.

• Acquire land at Vizag at existing facility for increasing capacity.
• Planning to buy land for Laurus Bio.
• Planning for separate Synthesis company as company is planning to expand well in these segment.
• Most of US sales is contract manufacturing

CAPEX:
• CAPEX spend is 700cr of which 50% is spend in API, 30% in FDF and 20% in Bio and Synthesis and further spending will be in similar ratio.
• Next 2 year CAPEX guidance is for 1500cr.
• Majority will got API, CRAMs and then formulation
• Bio will be allocated 60cr.

• Most of the API investment in next 2 year will be in Non ARV and Non Oncology.
• Broad based Asset Turnover to be 1.5.
• It will be based on internal accrual.

CSM:
• Co. have to multiple projects as until it is not started revenue is difficult to predict.
• Acquiring land for growth.
• Created a 100% subsidiary for Synthesis.
• FY 2023 onwards CSM expects to outpace grow more than other segment.

Laurus Bio:
• Facility will be commercialize by next 2 week and Sept end entirely commercialize.
• Have order book for the capacity.
• Process of acquiring land
• Target of creating Million Litre fermentation capacity next year.
• Target- 2x the revenue for segment.

ARV and Non ARV:
• Non ARV to ARV Revenue Ratio: 60:40.
• Next year share expected to be remain same.
• Main focus will be in volume growth than on price growth.
• Certain molecules grew well.
• ARV share of company has been higher now, hence co. eyeing growth from non NRV.

Formulation:
• Majorly its is volume growth and product growth.

Covid:
• It wont be part of opportunity for company both in terms of vaccine and medicines.

Acquiring talent:
• Continuous focus remains to acquire talent. Company is setting benchmark in Pharma sector for stock option.
• Company is facing no challenge to acquire talent.

Laurus Result: bseindia.com/xml-data/corpf…

For more discussion on Equity analysis

Subscribe to our YouTube channel 😃

Link 🔗: youtube.com/channel/UCDmd6…